Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.00    -1.00 (-0.20%)
Bid:
503.50
Ask:
504.50
Spread: 1.00 (0.199%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Directorate Change

24 Apr 2024 07:00

RNS Number : 7510L
Tate & Lyle PLC
24 April 2024
Β 

Β 

Tate & Lyle PLC - 24 April 2024

Β 

DIRECTORATE CHANGE

Β 

Tate & Lyle PLC (Tate & Lyle) announces that Dawn Allen, Chief Financial Officer, has decided to leave the Company to take up the position of Chief Financial Officer of Haleon plc. Mrs Allen will remain with Tate & Lyle until October 2024 to close out our half-year results ending 30 September 2024, and to support an orderly transition.

Β 

The Board has begun a process to appoint a successor to Mrs Allen and a further announcement will be made in due course.

Β 

Nick Hampton, Chief Executive said: "During her time at Tate & Lyle, Dawn has played a key role in maintaining strong financial discipline across the business, and leaves behind a proven team that will continue to support the delivery of our growth-focused strategy. We wish her every success in the next stage of her career."

Β 

David Hearn, Chair, said: "Dawn has been a valued member of the management team and on behalf of the Board I would like to thank her for her contribution to Tate & Lyle, and wish her all the best in her next role."

Β 

Β 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

Β 

Nick Hasell, FTI Consulting (Media)

Tel: +44 (0) 203 727 1340

Β 

Β 

About Tate & Lyle:

Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Β 

Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

Β 

We have more than 3,500 employees working in around 57 locations across 39 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Β 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2023, Tate & Lyle revenue from continuing operations totalled Β£1.75 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Linkedin, X (Twitter), Facebook or YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BOASELFIDELSEIL
Date   Source Headline
4th Jun 20269:25 amRNSForm 8.5 (EPT/RI)
3rd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20263:16 pmRNSForm 8.3 TATE & LYLE PLC
3rd Jun 20262:25 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
3rd Jun 20261:56 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
3rd Jun 20261:56 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20261:40 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 202611:57 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
3rd Jun 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:11 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
3rd Jun 202611:02 amRNS20260602_TATE & LYLE_8.5 EPT RI_UK_MLI
3rd Jun 202610:41 amRNSForm 8.3 - Tate & Lyle PLC
3rd Jun 202610:24 amRNSForm 8.5 (EPT/RI)
2nd Jun 20265:13 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
2nd Jun 20265:00 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
2nd Jun 20264:33 pmRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
2nd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
2nd Jun 20263:00 pmRNSForm 8.3 TATE & LYLE PLC
2nd Jun 20262:47 pmRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20262:30 pmRNSAnnual Financial Report and Notice of Meeting 2026
2nd Jun 202612:33 pmRNSForm 8.3 - Tate & Lyle PLC
2nd Jun 202611:47 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:45 amRNS20260601_TATE & LYLE_8.5 EPT RI_UK_MLI
2nd Jun 202611:44 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:32 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
2nd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20268:42 amRNSForm 8.5 (EPT/RI)
1st Jun 20265:27 pmRNS20260526_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:22 pmRNS20260526_TATELYLE8.5 EPT NON-RI BOFASE_replacement
1st Jun 20265:17 pmRNS20260522_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:10 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
1st Jun 20264:55 pmRNS20260521_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20263:35 pmRNSDirector/PDMR Shareholding
1st Jun 20263:30 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20263:20 pmRNSForm 8.3 TATE & LYLE PLC
1st Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20262:26 pmPRNInvesco Ltd: Form 8.3 - Tate & Lyle PLC; Public dealing disclosure
1st Jun 20262:17 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20262:12 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 202611:45 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
1st Jun 202611:37 amRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
1st Jun 202611:24 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
1st Jun 202611:20 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
1st Jun 202611:11 amBUSForm 8.3 - Tate & Lyle PLC
1st Jun 202611:00 amRNSTotal Voting Rights
1st Jun 202610:52 amRNSForm 8.3 – Tate & Lyle plc
1st Jun 202610:49 amRNS20260529_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
1st Jun 202610:47 amRNS20260529_TATE & LYLE_8.5 EPT RI_UK_MLI
1st Jun 202610:29 amRNSForm 8.3 - Tate & Lyle PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.